ME02696B - MODULATORI ORFAN RECEPTORA GAMA KOJI U VEZI SA RETINOIDIMA (ROR-GAMA) ZA UPOTREBU U LEĆENJU AUTOIMUNIH l INFLAMATORNIH BOLESTI - Google Patents

MODULATORI ORFAN RECEPTORA GAMA KOJI U VEZI SA RETINOIDIMA (ROR-GAMA) ZA UPOTREBU U LEĆENJU AUTOIMUNIH l INFLAMATORNIH BOLESTI

Info

Publication number
ME02696B
ME02696B MEP-2017-117A MEP2017117A ME02696B ME 02696 B ME02696 B ME 02696B ME P2017117 A MEP2017117 A ME P2017117A ME 02696 B ME02696 B ME 02696B
Authority
ME
Montenegro
Prior art keywords
methyl
compound
phenyl
chloro
methylnicotinamide
Prior art date
Application number
MEP-2017-117A
Other languages
German (de)
English (en)
French (fr)
Inventor
Fangbin Han
Hui Lei
Xichen Lin
Qinghua Meng
Yonghui Wang
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49709687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02696(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ME02696B publication Critical patent/ME02696B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Claims (21)

1.Jedinjenje formule I ili njegova farmaceutski prihvatljiva so gde: R1 je: - C1-C6 alkil; - metil supstituisan sa i) C3-C5 cikloalkilom; ii) fenoksi; ili iii) fenilom i drugi supstituent izabran iz grupe koju čine: metil, halo i metoksi; - etil supstituisan sa i) fenilom, pomenuti fenil je opciono supstituisan sa halo ili metoksi, ili ii) heteroarilom; - benzil, gde je fenil grupa pomenutog benzila opciono supstituisana sa halo, metoksi ili SO2CH2CH3; - C2 alkenil opciono susptituisan sa jednim F i jednim fenilom; - C3-C7 cikloalkil, pomenuti cikloalkil je opciono supstituisan sa jednim ili dva supstituenta izabrana iz grupe koju čine fenil, metil i F; ili pomenuti cikloalkil je opciono spojen sa fenil prstenom; - heterocikloalkil opciono supstituisan sa jednim ili dva C1-C3 alkila; - heteroaril opciono supstituisan sa jednim ili dva supstituenta izabrana iz grupe koju čine: C1- C3 alkil, C1-C3 alkoksi i CF3; i - fenil supstituisan sa jednim do tri susptituenta izabrana iz grupe koju čine: i) halo; ii) CN; iii) C1-C3 alkil opciono supstituisan sa jedan do tri F; iv) C1-C3 alkoksi; v) (CH2)nNRaRb; vi) C(O)CH3; i vii) CH2OCH3; R2 je halo ili C1-C3 alkil; R3 je halo ili metil; R4 je H ili metil; R5 je C1-C3 alkil; R6 je C1-C3 alkil; R7 je izabran iz grupe koju čine: - C1-C7 alkil opciono supstituisan sa jednim ili više supstituenata izabranih iz grupe koju čine halo, C3-C5 cikloalkil i CF3; - C3-C7 cikloalkil opciono supstituisan sa jednim ili više supstituenata izabranih iz grupe koju čine F, CH2F, CHF2, metil i metoksi, svaki k je 0 ili 1; svaki p je 0 ili 1; svaki n je 0, 1 ili 2; svaki Ra je H ili C1-C3 alkil; svaki Rb je H ili C1-C3 alkil;
2.Jedinjenje ili so prema zahtevu 1, gde je R1 heteroaril supstituisan sa C1-C3 alkil.
3.Jedinjenje ili so prema zahtevu 1 ili zahtevu 2, gde je R1 piridinil supstituisan sa metilom.
4.Jedinjenje ili so prema bilo kom od zahteva 1 do 3, gde je R2 metil.
5.Jedinjenje ili so prema bilo kom od zahteva 1 do 4, gde je k 1 i R3 je Cl ili F.
6.Jedinjenje ili so prema bilo kom od zahteva 1 do 5, gde je R4 H.
7.Jedinjenje ili so prema bilo kom od zahteva 1 do 6, gde je R5 metil.
8.Jedinjenje ili so prema bilo kom od zahteva 1 do 7, gde je p 0.
9.Jedinjenje ili so prema bilo kom od zahteva 1 do 8, gde je R7 C3-C6 cikloalkil opciono supstituisan sa jedinim ili dva F ili metilom.
10.Jedinjenje ili so prema bilo kom od zahteva 1 do 9, gde je R7 ciklobutil supstituisan sa metil ili dva F.
11.Jedinjenje ili so prema bilo kom od zahteva 1 to 9, gde je R7 ciklopentil.
12.Jedinjenje ili so prema zahtevu 1 gde je jedinjenje izabrano između: (S)-N-(3-((4-(ciklopentankarbonil)-3-metilpiperazin-1-il)metil)-5-fluoro-2-metilfenil)-2-metilpirimidin-5-karboksamida; (S)-N-(5-hloro-3-((4-(ciklopentankarbonil)-3-metilpiperazin-1-il)metil)-2-metilfenil)-6-metilnikotinamida; (S)-3-cijano-N-(3-((4-(3,3-difluorociklobutankarbonil)-3-metilpiperazin-1-il)metil)-5-fluoro-2-metilfenil)benzamida; (S)-N-(5-hloro-3-((4-(2-ciklopropilacetil)-3-metilpiperazin-1-il)metil)-2-metilfenil)-6-metilnikotinamida; N-(5-fluoro-2-metil-3-(((S)-3-metil-4-((cis)-3-metilciklobutankarbonil)piperazin-1-il)metil)fenil)-6-metilnikotinamida; N-(5-fluoro-2-metil-3-(((S)-3-metil-4-((trans)-3-metilciklobutanekarbonil)piperazin-1-il)metil)fenil)-6-metilnikotinamida; N-(5-hloro-2-metil-3-(((S)-3-metil-4-((trans)-3-metilciklobutankarbonil)piperazin-1-il)metil)fenil)-6-metilnikotinamida; N-(5-hloro-2-metil-3-(((S)-3-metil-4-((cis)-3-metilciklobutankarbonil)piperazin-1-il)metil)fenil)-6-metilnikotinamida; N-(5-hloro-2-metil-3-(((S)-3-metil-4-((cis)-3-metilciklobutanekarbonil)piperazin-1-il)metil)fenil)-2-metilpirimidin-5-karboksamida; N-(5-hloro-2-metil-3-(((S)-3-metil-4-((trans)-3-metilciklobutankarbonil)piperazin-1-il)metil)fenil)-2-metilpirimidin-5-karboksamida; i (S)-N-(5-hloro-3-((4-(ciklopentanekarbonil)-3-metilpiperazin-1-il)metil)-2-metilfenil)-2-metilpirimidin-5-karboksamida.
13.Jedinjenje prema zahtevu 1 koje je (S)-3-cijano-N-(3-((4-(ciklopentanekarbonil)-3-metilpiperazin-1-il)metil)-5-fluoro-2-metilfenil)benzamid; ili njegova farmaceutski prihvatljiva so.
14.Jedinjenje prema zahtevu 1 koje je (S)-N-(5-hloro-3-((4-(ciklopentanekarbonil)-3-metilpiperazin-1-il)metil)-2-metilfenil)-6-metilnikotinamid; ili njegova farmaceutski prihvatljiva so.
15.(S)-N-(5-Hloro-3-((4-(ciklopentanekarbonil)-3-metilpiperazin-1-il)metil)-2-metilfenil)-6-metilnikotinamid Formule:
16.Jedinjenje prema zahtevu 1 koje je N-(5-hloro-2-metil-3-(((S)-3-metil-4-((cis)-3-metilciklobutankarbonil)piperazin-1-il)metil)fenil)-6-metilnikotinamid; ili njegova farmaceutski prihvatljiva so.
17.Jedinjenje prema bilo kom od zahteva 1 do 16 ili njegova farmaceutski prihvatljiva so za upotrebu u terapiji.
18.Jedinjenje prema bilo kom od zahteva 1 do 16 ili njegova farmaceutsko prihvatljiva so za upotrebu u lečenju psorijaze.
19.(S)-N-(5-Hloro-3-((4-(ciklopentanekarbonil)-3-metilpiperazin-1-il)metil)-2-metilfenil)-6-metilnikotinamid za upotrebu u lečenju psorijaze.
20.Farmaceutska kompozicija koja sadrži jedinjenje formule I prema bilo kom od zahteva 1 do 16 ili njegova farmaceutski prihvatljiva so i farmaceutski prihvatljiv nosač ili ekscipijent.
21.Farmaceutska kompozicija koja sadrži (S)-N-(5-hloro-3-((4-(ciklopentanekarbonil)-3-metilpiperazin-1-il)metil)-2-metilfenil)-6-metilnikotinamid i farmaceutski prihvatljiv nosač ili ekscipijent.
MEP-2017-117A 2012-12-06 2013-12-05 MODULATORI ORFAN RECEPTORA GAMA KOJI U VEZI SA RETINOIDIMA (ROR-GAMA) ZA UPOTREBU U LEĆENJU AUTOIMUNIH l INFLAMATORNIH BOLESTI ME02696B (me)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2012001636 2012-12-06
CN2013000182 2013-02-25
CN2013000803 2013-07-01
PCT/EP2013/075594 WO2014086894A1 (en) 2012-12-06 2013-12-05 Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases
EP13799318.4A EP2928885B1 (en) 2012-12-06 2013-12-05 Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases

Publications (1)

Publication Number Publication Date
ME02696B true ME02696B (me) 2017-10-20

Family

ID=49709687

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2017-117A ME02696B (me) 2012-12-06 2013-12-05 MODULATORI ORFAN RECEPTORA GAMA KOJI U VEZI SA RETINOIDIMA (ROR-GAMA) ZA UPOTREBU U LEĆENJU AUTOIMUNIH l INFLAMATORNIH BOLESTI

Country Status (33)

Country Link
US (1) US10005731B2 (me)
EP (2) EP3219711A1 (me)
JP (1) JP6279605B2 (me)
KR (1) KR20150092244A (me)
CN (1) CN105121430B (me)
AR (1) AR093818A1 (me)
AU (1) AU2013354109B2 (me)
BR (1) BR112015013137B1 (me)
CA (1) CA2894016C (me)
CL (1) CL2015001557A1 (me)
CR (1) CR20150302A (me)
CY (1) CY1118932T1 (me)
DK (1) DK2928885T3 (me)
EA (1) EA026437B1 (me)
ES (1) ES2626390T3 (me)
HR (1) HRP20170638T1 (me)
HU (1) HUE033212T2 (me)
IL (1) IL239082A0 (me)
LT (1) LT2928885T (me)
ME (1) ME02696B (me)
MX (1) MX2015007180A (me)
PE (1) PE20151144A1 (me)
PH (1) PH12015501244A1 (me)
PL (1) PL2928885T3 (me)
PT (1) PT2928885T (me)
RS (1) RS55875B1 (me)
SG (1) SG11201504200TA (me)
SI (1) SI2928885T1 (me)
SM (1) SMT201700281T1 (me)
TW (1) TW201427959A (me)
UY (1) UY35174A (me)
WO (1) WO2014086894A1 (me)
ZA (1) ZA201503666B (me)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9745297B2 (en) 2013-07-30 2017-08-29 Boehringer Ingelheim International Gmbh Compounds as modulators of RORC
EA031804B1 (ru) 2014-02-03 2019-02-28 Вайтаи Фармасьютиклз, Инк. Дигидропирролопиридиновые ингибиторы ror-гамма
ES2716966T3 (es) * 2014-05-28 2019-06-18 Glaxosmithkline Ip Dev Ltd Derivados de piperazina como moduladores de ROR-gamma
KR20170012388A (ko) 2014-05-28 2017-02-02 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 신규 화합물
JP6759110B2 (ja) * 2014-05-28 2020-09-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 新規な化合物
CN104292208A (zh) * 2014-09-09 2015-01-21 上海师范大学 7-苯基-6,8-二氧杂螺[3.5]壬烷-2-羧酸及其制备方法
MA40759A (fr) 2014-09-26 2017-08-01 Pfizer Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation
SI3207043T1 (sl) 2014-10-14 2019-04-30 Vitae Pharmaceuticals, Inc. Dihidropirolopiridinovi inhibitorji za ROR-gama
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
TW201625588A (zh) * 2014-11-05 2016-07-16 第一三共股份有限公司 環狀胺衍生物
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
WO2016120849A1 (en) * 2015-01-30 2016-08-04 Pfizer Inc. Methoxy-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof
WO2017024018A1 (en) 2015-08-05 2017-02-09 Vitae Pharmaceuticals, Inc. Modulators of ror-gamma
CN108463458B (zh) * 2015-11-20 2022-02-01 生命医药有限责任公司 ROR-γ的调节剂
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
BR112019000486A2 (pt) * 2016-07-13 2019-04-24 Leo Pharma A/S composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar psoríase
CN109134476B (zh) * 2017-06-15 2021-03-19 复旦大学 桥环哌嗪类衍生物或其盐及其制备方法和用途
JP6737967B1 (ja) * 2017-07-18 2020-08-12 ロンザ リミテッドＬｏｎｚａ Ｌｉｍｉｔｅｄ ５−フルオロ−２−メチル−３−ニトロ安息香酸およびそのメチルエステルを製造する方法
WO2019023207A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. Inhibitors of rorϒ
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
CN108752185A (zh) * 2018-07-17 2018-11-06 成都道合尔医药技术有限公司 一种1-氟-环戊甲酸的合成方法
CN109438423A (zh) * 2018-09-12 2019-03-08 通化师范学院 一种肺癌靶向化合物azd-3759的合成工艺的新方法
CN110862319A (zh) * 2019-12-04 2020-03-06 深圳振强生物技术有限公司 奥扎格雷杂质的制备方法
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790726B2 (en) 2005-08-16 2010-09-07 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
US7825120B2 (en) * 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
US20070208000A1 (en) * 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
EP1962852B1 (en) * 2005-12-19 2017-01-25 Cytokinetics, Inc. Compounds, compositions and methods
WO2012028100A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012027965A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012100734A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Compounds useful as retinoid-related orphan receptor gamma modulators
WO2012100732A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof
EP2511263A1 (en) * 2011-04-14 2012-10-17 Phenex Pharmaceuticals AG Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
WO2012145254A2 (en) * 2011-04-16 2012-10-26 Board Of Regents, The University Of Texas System Methods of using inhibitors of rorϒt to treat disease
JP5902029B2 (ja) 2011-04-28 2016-04-13 日本たばこ産業株式会社 アミド化合物およびその医薬用途
WO2012158784A2 (en) * 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror
JP2014528933A (ja) 2011-09-09 2014-10-30 ニューヨーク ユニバーシティ ＲＯＲγｔモジュレーターとしてのアミド化合物およびその使用
GB201116641D0 (en) 2011-09-27 2011-11-09 Glaxo Group Ltd Novel compounds
GB201207406D0 (en) 2012-04-27 2012-06-13 Glaxo Group Ltd Novel compounds
MX2014012989A (es) 2012-04-27 2015-01-22 Glaxo Group Ltd Compuestos novedosos.
WO2013171729A2 (en) 2013-01-08 2013-11-21 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl amide compounds as rorgamat modulator
US10286000B2 (en) 2013-10-25 2019-05-14 St. Jude Children's Research Hospital, Inc. Retinoid X receptor-gamma agonists and retinoid X receptor-alpha antagonists for treatment of cancer
KR20160068799A (ko) 2013-10-25 2016-06-15 글락소스미스클라인 엘엘씨 신규 화합물
ES2716966T3 (es) 2014-05-28 2019-06-18 Glaxosmithkline Ip Dev Ltd Derivados de piperazina como moduladores de ROR-gamma
KR20170012388A (ko) 2014-05-28 2017-02-02 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 신규 화합물
JP6759110B2 (ja) 2014-05-28 2020-09-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 新規な化合物

Also Published As

Publication number Publication date
SG11201504200TA (en) 2015-06-29
UY35174A (es) 2014-06-30
US20150299121A1 (en) 2015-10-22
DK2928885T3 (en) 2017-05-15
BR112015013137B1 (pt) 2022-05-10
RS55875B1 (sr) 2017-08-31
EP2928885B1 (en) 2017-03-22
US10005731B2 (en) 2018-06-26
CY1118932T1 (el) 2018-01-10
CR20150302A (es) 2015-08-10
HRP20170638T1 (hr) 2017-06-30
WO2014086894A1 (en) 2014-06-12
JP6279605B2 (ja) 2018-02-14
IL239082A0 (en) 2015-07-30
CA2894016C (en) 2020-12-22
AR093818A1 (es) 2015-06-24
CL2015001557A1 (es) 2015-10-02
HUE033212T2 (hu) 2017-11-28
ZA201503666B (en) 2016-02-24
KR20150092244A (ko) 2015-08-12
MX2015007180A (es) 2015-10-14
PH12015501244A1 (en) 2015-08-10
BR112015013137A2 (pt) 2017-07-11
PT2928885T (pt) 2017-06-30
CN105121430A (zh) 2015-12-02
EP2928885A1 (en) 2015-10-14
ES2626390T3 (es) 2017-07-24
AU2013354109A1 (en) 2015-06-11
PL2928885T3 (pl) 2017-09-29
LT2928885T (lt) 2017-05-25
SI2928885T1 (sl) 2017-06-30
TW201427959A (zh) 2014-07-16
AU2013354109B2 (en) 2016-06-16
JP2016501250A (ja) 2016-01-18
EA201591059A1 (ru) 2015-09-30
PE20151144A1 (es) 2015-08-02
HK1214814A1 (en) 2016-08-05
EA026437B1 (ru) 2017-04-28
CN105121430B (zh) 2017-06-16
EP3219711A1 (en) 2017-09-20
CA2894016A1 (en) 2014-06-12
SMT201700281T1 (it) 2017-07-18

Similar Documents

Publication Publication Date Title
ME02696B (me) MODULATORI ORFAN RECEPTORA GAMA KOJI U VEZI SA RETINOIDIMA (ROR-GAMA) ZA UPOTREBU U LEĆENJU AUTOIMUNIH l INFLAMATORNIH BOLESTI
PE20070528A1 (es) Compuestos heterociclicos como ligandos del receptor vaniloide del subtipo 1
NZ603594A (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
EA201400553A1 (ru) Производные 2-(1,2,3-триазол-2-ил)бензамида и 3-(1,2,3-триазол-2-ил)пиколинамида
NZ603198A (en) Novel hydroxamic acid derivative
MY177250A (en) Novel nicotinamide derivative or salt thereof
JP2016501250A5 (me)
NZ595759A (en) Substituted phenylureas and phenylamides as vanilloid receptor ligands
PE20151091A1 (es) Agentes inductores de apoptosis para el tratamiento de cancer y enfermedades inmunes y autoinmunes
HRP20180483T1 (hr) Spoj kinolona
EA201290574A1 (ru) Новое производное 3-гидрокси-5-арилизотиазола
ME02382B (me) 2-(2,4,5-supstituisani-anilino) piramidisnki derivati kao egfr modulatori korisni za tretman raka
JP2013510122A5 (me)
NZ612000A (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
MX2015013348A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos.
EP4467549A3 (en) Intermediates of n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives
AR063946A1 (es) Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
ME02766B (me) Derivati arilmetoksi izoindolina i kompozicije koje ih obuhvataju i postupci njihove primene
NZ708508A (en) Methods of treatment using selective bcl-2 inhibitors
NZ593030A (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
NZ612544A (en) Heterocyclic compounds suitable for the treatment of dyslipidemia
MX2010009401A (es) Forma cristalina de derivado de fenilamino pirimidina.
NZ604035A (en) Glycine transporter-1 inhibitors, methods of making them, and uses thereof
CN109311852A (zh) 作为egfr抑制剂的苯胺嘧啶化合物的结晶
MX2023001803A (es) Derivados de 2,4-diaminoquinazolina y usos medicos de los mismos.